Carnick & Kubik Group LLC grew its position in Biogen Inc (NASDAQ:BIIB) by 7.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,663 shares of the biotechnology company’s stock after purchasing an additional 388 shares during the quarter. Carnick & Kubik Group LLC’s holdings in Biogen were worth $1,804,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Biogen by 77.0% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 174 shares during the last quarter. Horan Capital Advisors LLC. acquired a new position in shares of Biogen in the third quarter valued at approximately $128,000. Massey Quick Simon & CO. LLC grew its position in shares of Biogen by 84.8% in the third quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 195 shares during the last quarter. Gs Investments Inc. acquired a new position in shares of Biogen in the second quarter valued at approximately $136,000. Finally, Patten Group Inc. grew its position in shares of Biogen by 4,308.7% in the third quarter. Patten Group Inc. now owns 20,368 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 19,906 shares during the last quarter. 87.79% of the stock is currently owned by institutional investors.

Shares of Biogen Inc (NASDAQ:BIIB) opened at $316.99 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.34. Biogen Inc has a 12 month low of $244.28 and a 12 month high of $370.57. The firm has a market capitalization of $66,987.10, a price-to-earnings ratio of 14.52, a price-to-earnings-growth ratio of 1.65 and a beta of 0.75.

Biogen (NASDAQ:BIIB) last released its earnings results on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share for the quarter, missing the consensus estimate of $5.44 by ($0.18). Biogen had a return on equity of 38.32% and a net margin of 20.69%. The business had revenue of $3.31 billion for the quarter, compared to the consensus estimate of $3.08 billion. During the same quarter in the previous year, the company earned $5.04 earnings per share. The firm’s revenue for the quarter was up 15.1% on a year-over-year basis. equities analysts anticipate that Biogen Inc will post 24.88 EPS for the current fiscal year.

In other Biogen news, Director Robert W. Pangia sold 5,832 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the completion of the sale, the director now directly owns 23,539 shares in the company, valued at $7,759,631.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michel Vounatsos bought 780 shares of the business’s stock in a transaction on Friday, December 29th. The shares were acquired at an average price of $320.55 per share, with a total value of $250,029.00. The disclosure for this purchase can be found here. Insiders have acquired 31,560 shares of company stock valued at $10,020,858 over the last 90 days. Corporate insiders own 0.25% of the company’s stock.

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Biogen in a research report on Thursday, February 8th. Canaccord Genuity reaffirmed a “hold” rating and issued a $350.00 target price on shares of Biogen in a research report on Wednesday, February 7th. Oppenheimer upped their target price on Biogen from $380.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, January 26th. Mizuho reaffirmed a “buy” rating and issued a $433.00 target price (up previously from $400.00) on shares of Biogen in a research report on Sunday, February 4th. Finally, Credit Suisse Group raised Biogen to a “buy” rating and set a $384.00 target price on the stock in a research report on Wednesday, February 7th. Eight analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $368.99.

ILLEGAL ACTIVITY NOTICE: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2018/02/14/carnick-kubik-group-llc-boosts-stake-in-biogen-inc-biib.html.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.